Bragar Eagel & Squire is Investigating Certain Officers and Directors of Live Ventures, CorMedix, Emergent BioSolutions, and Generac on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm


NEW YORK, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors of Live Ventures Incorporated (NASDAQ: LIVE), CorMedix Inc. (NASDAQ: CRMD), Emergent BioSolutions, Inc. (NYSE: EBS), and Generac Holdings Inc. (NYSE: GNRC) on behalf of long-term stockholders. More information about each potential case can be found at the link provided.

Live Ventures Incorporated (NASDAQ: LIVE)

Bragar Eagel & Squire is investigating certain officers and directors of Live Ventures Incorporated following a class action complaint that was filed against Live Ventures on August 13, 2021.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that Live’s earnings per share for FY 2016 was actually only $6.33 per share; (2) that the Company used an artificially low share count to boost the earnings per share by 40%; (3) that Live had overstated pre-tax income for fiscal 2016 by 20% by including $915,500 of “other income” related to certain amendments that were not negotiated until after the close of the fiscal year; (4) that Live’s acquisition of ApplianceSmart did not close during first quarter 2017; (5) that using December 30, 2017 as the “acquisition date” and recognizing income therefrom did not conform to generally accepted accounting principles; (6) that, by falsely stating that the acquisition closed during the quarter, Live recognized bargain purchase gain, which enabled the Company to report positive net income in what would otherwise have been an unprofitable quarter; (7) that between fiscal 2016 and fiscal 2018, Live’s CEO received approximately 94% more in compensation than was disclosed to investors; and (8) as a result, Defendants’ statements about its business, operations, and prospects were materially false and misleading and/or lacked reasonable basis at all relevant times.

To learn more about our investigation into Live Ventures go to: https://bespc.com/cases/LIVE

CorMedix Inc. (NASDAQ: CRMD)

Bragar Eagel & Squire is investigating certain officers and directors of CorMedix Inc. following a class action complaint that was filed against CorMedix on July 22, 2021.

The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants made material misrepresentations concerning the following: (i) deficiencies existed with respect to DefenCath’s manufacturing process and/or at the facility responsible for manufacturing DefenCath; (ii) in light of the foregoing deficiencies, the FDA was unlikely to approve the DefenCath NDA for CRBSIs in its present form; (iii) Defendants had downplayed the true scope of the deficiencies with DefenCath’s manufacturing process and/or at the facility responsible for manufacturing DefenCath; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

To learn more about our investigation into CorMedix go to: https://bespc.com/cases/CRMD

Emergent BioSolutions, Inc. (NYSE: EBS)

Bragar Eagel & Squire is investigating certain officers and directors of Emergent BioSolutions, Inc. following a class action complaint that was filed against Emergent on April 19, 2021.

According to the filed complaint: (i) Emergent’s Baltimore plant had a history of manufacturing issues increasing the likelihood for massive contaminations; (ii) these longstanding contamination risks and quality control issues at Emergent’s facility led to a string of FDA citations; (iii)the Company previously had to discard the equivalent of millions of doses of COVID-19 vaccines after workers at the Baltimore plant deviated from manufacturing standards; and (iv) as a result of the foregoing, Defendants’ public statements about Emergent’s ability and capacity to mass manufacture multiple COVID-19 vaccines at its Baltimore manufacturing site were materially false and misleading and lacked a reasonable basis.

To learn more about our investigation into Emergent go to: https://bespc.com/cases/EBS

Generac Holdings Inc. (NYSE: GNRC)

Bragar Eagel & Squire is investigating certain officers and directors of Generac Holdings Inc. following a class action complaint that was filed against Generac on August 20, 2021.

The complaint alleges that throughout the Class Period, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Generac’s portable generators posed an unreasonable risk of injury to users and the public; (2) as a result, at least seven finger amputations and one crushed finger had been reported to the Company; (3) as a result, Generac would face increased regulatory scrutiny; (4) the Company would end sales in its Generac® and DR® 6500 Watt and 8000 Watt portable generators in the United States and Canada in June 2021; (5) the Company would recall its Generac® and DR® 6500 Watt and 8000 Watt portable generators in the United States and Canada; (6) the end of sales and the recall would occur before the Company’s noted hurricane and wildfire seasons and following the Texas outage—periods the Company has touted for sales; and (7) as a result, defendants’ public statements and statements to journalists were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To learn more about our investigation into Generac go to: https://bespc.com/cases/GNRC

About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Alexandra B. Raymond, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com